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Utilization of free medication samples in the United States in a 
nationally representative sample: 2009–2013
Joshua D. Brown, Pharm.D., M.S.*, Pratik A. Doshi, M.S., and Jeffery C. Talbert, Ph.D.
Institute for Pharmaceutical Outcomes & Policy, Department of Pharmacy Practice & Science, 
University of Kentucky College of Pharmacy, 789 S. Limestone St #292E, Lexington, KY, USA
Abstract
Background—Manufacturers provide free sample medications as a means to increase use of 
branded medications. Sample use varies year-to-year as branded product patents expire and new 
products come to market.
Objective—This study sought to describe the use of sample medications during 2009–2013 and 
assess individual characteristics associated with sample use.
Methods—Data from the 2009–2013 U.S. Medical Expenditure Panel Survey (MEPS) were 
used. MEPS asks participants whether they received each medication they are taking as a sample. 
The top 10 medications and medication classes used each year by volume were identified as well 
as the proportion of people who used at least one sample medication. The proportion of new 
initiators of medications were also classified as the percent who received a sample for the specific 
medication. Logistic regression was used to assess individual demographics, insurance, and 
medication characteristics associated with use.
Results—Prevalence of sample use ranged from 9.3% in 2009 to 6.2% in 2013. The most widely 
used sample medications included statins during 2009–2011, which changed to inhaled β-agonists 
in 2012–2013, as atorvastatin became available as a generic. The overall volume of the top 10 free 
sample medications decreased by one-third over this study period. In 2013, 12.6% of new insulin 
analog users and 11.0% of new oral contraceptive users receive these medications through 
samples. Regression analysis showed that U.S. Medicaid- and Medicare-insured persons were less 
likely to use samples compared to those with private insurance.
Conclusions—Sample medication use has decreased as generic medications are becoming more 
used in the U.S.
Keywords
Sample medications; Generic drugs; Pharmaceutical marketing; Physician prescribing
*Corresponding author. Tel.: +1 479 650 8047; fax: +1 859 323 0069. josh.brown@uky.edu (J.D. Brown). 
Conflicts of interest: None.
HHS Public Access
Author manuscript
Res Social Adm Pharm. Author manuscript; available in PMC 2017 December 20.
Published in final edited form as:
Res Social Adm Pharm. 2017 ; 13(1): 193–200. doi:10.1016/j.sapharm.2016.01.006.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Introduction
Free medication samples are widely disbursed to prescribers as a marketing tool for trade 
name products. In 2005, the total value of medications provided was approximately $18 
billion, with up to 20% of all Americans and nearly 50% of Medicare beneficiaries utilizing 
samples annually.1,2 This practice is seen as pervasive by some medical associations and 
patient advocacy groups but is typically viewed positively by prescribers and patients.3,4 As 
implied, patients receive the medications for free and avoid immediate costs of the 
medication at the point of care. Therapy is initiated immediately without a pharmacy visit 
and the prescriber has the opportunity to provide medication counseling, which can be 
important for certain dosage forms or devices.5
Despite the perceived benefits, pharmaceutical companies intend the practice as a means to 
increase use of branded medications. This can lead to increased use of more expensive 
branded products, which increases costs to both patients and third-party payers if the 
sampled medication is continued versus a suitable generic alternative.6–9 Further, use of 
sample medications forgoes the typical process of prescribing and dispensing and removes 
the medication experts – pharmacists – from their roles in screening for potential drug– drug 
and drug–disease interactions and in providing medication counseling.10
Medication sample use is difficult to analyze as the practice circumvents the process of 
recording filled medications at the pharmacy or in insurance billing claims. Previous studies 
have utilized the U.S. Medical Expenditure Panel Survey (MEPS) to investigate sample use 
given that it provides a self-reported estimate of sample use in a nationally representative 
weighted sample.11,12 These studies have looked at medication use through 2005 and have 
identified individual characteristics associated with sample medication use. Medication 
samples and the individuals utilizing them will vary by time as medication patent life expires 
and because generic medication use has become more prevalent over the last decade. Thus, 
this study sought to update the information regarding sample medication use in the U.S. 
during the most recent five-year period available in MEPS (2009–2013). Medications used 
as samples were identified and the individual characteristics associated with sample use in 
the most recent year (2013) were also explored.
Methods
Data sources
MEPS data were used to estimate the scope of free sample use and to characterize the 
typical user. MEPS data are de-identified and publicly available and contain information on 
patient demographics, sources of payment, medical service and pharmaceutical medication 
utilization and expenditures. Due to the public and de-identified nature of these data, they 
are exempt from an institutional review board approval process.
Study population and design
Data from years 2009–2013 were used to conduct a cross-sectional study that looked at the 
disbursement of free medication samples in the U.S. over this time period. The most recent 
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year available, 2013, was used to evaluate the individual characteristics of sample users. 
There were no exclusions applied to the study sample.
Sample prescription medication use
MEPS provided “Prescribed Medicines” files that contain information on prescription 
medication use. Survey respondents are first asked about the medications they use and if 
they received any of these medications as free samples. Any patient that identified at least 
one of their medications as a free sample was considered a sample user for the study. 
Patients are also asked to identify if they are a new user of a particular medication for the 
respective year. The “Prescribed Medicines” file includes medication information for each 
person and Generic Product Identifier (GPI) codes (Medi-Span, Indianapolis, IN) were used 
to identify medications including all formulations for each medication. Using weights from 
expenditure files provided by MEPS, the top 10 classes of medications and top 10 
medications for each year of the data from 2009 to 2013 by volume were determined as well 
as the percent of the population using sample medications each year. Additionally, for new 
users of any medications in each year, the percent of patients receiving free sample for that 
particular medication in the given year was reported.
Sample users characteristics in 2013
MEPS 2013 “Full Year Consolidated” files contained demographic information on the 
respondents. Race and ethnicity were combined into a single variable with the following 
categories: Hispanics, non-Hispanic Whites, non-Hispanic Blacks and non-Hispanics that 
belonged to other races. A new medical insurance indicator was created from variables 
available in the data, and it consisted of the following insurance provider categories: Private, 
Medicaid, Medicare (dual eligibles were classified in the Medicaid group), other public 
insurance, and uninsured. Additionally, an indicator for prescription medication insurance 
was included. Educational status was collapsed into two levels: lower than high school, and 
at least high school level. Family income, as a percentage of the annual Federal Poverty 
Limit (FPL), was classified for income <100% of FPL, ≥100 and <125% of FPL, ≥125% 
and <200% of FPL, ≥200% and <400% of FPL, ≥400% of FPL. Geographic region was 
based on U.S. Census regions. The total number of prescription medications used by each 
individual in 2013 was also calculated.
Statistical analyses
All statistical analyses were conducted using SAS 9.4 (Cary, North Carolina). SAS survey 
commands were utilized to incorporate survey weights provided by MEPS; this allows the 
generalization of results to represent the national population based on race, gender, age, and 
geographic factors. Weighted counts and frequencies are reported for patient characteristics 
for the year 2013. Chi-square tests were used to compare across categorical variables. A 
multiple logistic regression model was performed to identify factors associated with the 
receipt of any sample medications for 2013. This model included patient demographics, 
access to care variables, and the count of total prescription medications. Odds ratios and 
95% CI are reported. The significance level for the study was set at α < 0.05.
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Results
Medications used as samples
Over the time period 2009–2013, prevalence of sample medication use decreased in the U.S. 
from 9.3% in 2009 to 6.2% in 2013. Table 1 shows the top 10 individual medications and 
medication classes used as samples by volume. During 2009–2011, HMG Co-A reductase 
inhibitors (“statins”) were the most widely used sample medications, with a volume of 
roughly 1.3 million samples each year. This group consisted mostly of rosuvastatin and 
atorvastatin. Statins were supplanted by inhaled β-agonists, as atorvastatin lost patent 
protection heading into 2012. Some medications widely available as generics but with 
branded versions were in the top 10 in 2013, such as levothyroxine. Other highly used free 
sample medication classes in 2013 included non-steroid anti-inflammatory drugs (NSAIDs), 
proton pump inhibitors (PPIs), insulin analogs, and oral contraceptives. The total volume of 
samples utilized in the top 10 medication classes decreased by over one-third between 2009 
and 2013 (9 million to 6 million). For those under 18 years of age, asthma medications were 
the highest utilized classes. For non-elderly adults, more variation was present with inhaled 
β-agonists, anti-depressants, and statins being highly used, among others. For elderly 
individuals, inhaled β-agonists (±steroids), statins, and β-blockers (oral and ophthalmic) 
were highly utilized.
Table 2 shows the percent of people who were new initiators of each medication class who 
used a sample for that class. For example, in 2009, 5.2% of statin initiators used a statin 
sample while in 2013 only 2.8% did. In 2013, the highest initiators using samples were 
among insulin users (12.6%), selective norepinephrine reuptake inhibitors (SNRIs; 13.9%), 
and oral contraceptives (11.0%).
Characteristics of free sample users
Characteristics of samples users and non-users in 2013 are summarized in Table 3. The total 
weighted sample represented nearly 180 million people in the U.S. who filled a prescription 
medication. Table 4 shows the adjusted comparisons of users and non-users with adjusted 
odds ratios (aOR) and 95% confidence intervals (CI). Gender, age, race, prescription drug 
coverage, family income, and region were all non-significant predictors of sample use. 
Those with Medicaid (aOR = 0.63, 95% CI 0.43–0.92) or Medicare (aOR = 0.56, 95% CI 
0.34–0.95) insurance were less likely to use samples compared to those with private 
insurance. Other public insurance and uninsured status was not associated with sample use 
compared to the ‘Private’ reference group. Those with high school or higher education had 
17–98% higher odds of being sample users compared to those with less than a high school 
education. Also, for each additional prescription medication filled, the odds of sample used 
increased by roughly 1–2%. The c-statistic for the model was 0.649, showing low model 
discriminatory power for sample users.
Discussion
Year-to-year variability was observed in the medications sampled, which is associated with 
patent expiry and new medications coming onto the market throughout the time period. 
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Thus, the characteristics of free sample users are likely to change as new disease states are 
treated by these sampled medications. Also observed was an overall decrease in sample use 
as measured by the prevalence of sample users as well as the total volume of sample use. 
This is attributed to the increase in generic utilization (85% of all prescriptions by volume) 
overall in the U.S. as the number of block-bluster branded products have decreased.13 
Despite decreasing prevalence, sample medications have a tremendous economic impact7,14 
and can also influence research on products available through samples.15
Sample medications are provided as a means of pharmaceutical marketing of branded 
products, even when direct (i.e. same chemical entity) or therapeutic (i.e. same therapeutic 
class) substitutes exist.7 While the practice has been defended as a means to provide 
medications to those without insurance,16 this does not appear to be the case in this study or 
in previous literature,11,12 and is counterintuitive, as uninsured individuals have fewer means 
to attain branded products once the sample supply is extinguished. Cost implications 
associated with this practice can impact individual out-of-pocket spending as well as third-
party payer costs. This is especially concerning when low-cost generic programs are widely 
prevalent and provide access to affordable medications regardless of insurance.17,18
A study by Duru et al investigated the potential cost savings associated with both direct and 
therapeutic substitution among diabetic patients with Medicare Part D coverage.7 They 
found that direct substitution would save approximately $150 dollars per person and 
therapeutic substitution would save $400 per person. Among the top ten medications in 
2013, only levothyroxine was available as a generic. However, this is also an example where 
substitution may not necessarily confer equivalence, as levothyroxine products have been 
shown to vary in their bioavailability.19,20 Other examples include warfarin, estrogens, and 
anticonvulants, which were also in the top 20 of all free sample drugs (data not shown).21 
This further highlights the marketing strategy of free sample medications, as a patient could 
not necessarily move from the sample branded product to a generic version without a 
potential dose adjustment. Therapeutic substitution implies equivalence within a class, 
which is arguable for a number of the Top 10 sampled classes including statins, NSAIDs, 
PPIs, and SNRIs.22
Limitations
This study is subject to some limitations. Primarily, sample use is self-reported by MEPS 
participants who could misunderstand the question or have recall bias, although participants 
are led through the survey by trained personnel. Other important medications by 
expenditures, such as self-injected biologics, were also observed but not reportable due to 
low sample sizes. The a priori objectives of this study were also to investigate individual 
access to care characteristics as well as provider characteristics that were may be predictive 
of sample use. However, a high number of missing responses were observed, limiting the 
usefulness of these variables. Further, the adjusted model showed low discriminatory power 
for sample users. This suggests that other individual characteristics, or prescriber 
characteristics, may be predictive of sample use other than those variables included here.
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Conclusion
In the United States, 6.2% of prescription medication users used a free sample medication. 
The types of medications used as samples changes annually as medications patent life 
expires or new medications enter the market. Sample medications have tremendous cost 
implications, especially when direct or therapeutic generic substitutes exist.
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Table 4
Results of multiple logistic regression predicting use of sample medications in 2013
Adjusted odds ratio 95% CI P-value
Gender
 Male Ref. Ref. Ref.
 Female 1.14 0.96, 1.36 0.1481
Age categories
 Less than 18 years Ref. Ref. Ref.
 18–34 years 0.81 0.50, 1.30 0.3835
 35–64 years 1.10 0.73, 1.68 0.6453
 65–74 years 1.16 0.72, 1.87 0.5504
 75 years and above 1.27 0.73, 2.22 0.3918
Race
 non-Hispanic Whites Ref. Ref. Ref.
 Hispanics 1.19 0.94, 1.51 0.1428
 non-Hispanic Blacks 0.89 0.73, 1.10 0.2958
 Asians 1.15 0.77, 1.72 0.4864
 Others 0.92 0.53, 1.58 0.7527
Medical insurance coverage
 Private insurance Ref. Ref. Ref.
 Medicaid 0.63 0.43, 0.92 0.0155
 Medicare 0.56 0.34, 0.95 0.0303
 Other public insurance 0.88 0.52, 1.49 0.6205
 Uninsured 1.19 0.80, 1.77 0.3909
Prescription drug insurance coverage
 No Ref. Ref. Ref.
 Yes 0.74 0.52, 1.03 0.0759
Educational status
 Less than high school Ref. Ref. Ref.
 At least high school and higher 1.52 1.17, 1.98 0.0021
 Status missing 1.03 0.62, 1.72 0.9089
Poverty status (family income)
 <100% of FPL Ref. Ref. Ref.
 ≥100 and <125% of FPL 1.00 0.68, 1.47 0.9876
 ≥125 and <200% of FPL 1.07 0.74, 1.55 0.7291
 ≥200 and <400% of FPL 0.81 0.56, 1.17 0.2656
 ≥400% of FPL 0.83 0.58, 1.17 0.2847
Region
 Northeast Ref. Ref. Ref.
 Midwest 0.98 0.69, 1.41 0.9261
 South 1.18 0.87, 1.62 0.2898
 West 0.82 0.58, 1.18 0.2873
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Adjusted odds ratio 95% CI P-value
Number of prescriptions 1.02 1.01, 1.02 <0.0001
FPL = federal poverty limit; CI = confidence interval.
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